Lurbinectedin for Second-Line Treatment of Patients with Metastatic SCLC

2020 Year in Review - Lung Cancer - Lung Cancer

Lurbinectedin is an effective second-line treatment for patients with advanced SCLC who have progressed after platinum-based chemotherapy.

There are few treatment options for patients with SCLC who progress after first-line platinum-containing therapy regimens.1 A phase 2 study was conducted to evaluate the activity and safety of lurbinectedin (Zepzelca), a selective inhibitor of oncogenic transcription, in patients with SCLC who progressed after receiving platinum-based chemotherapy.1

This single-arm, open-label, phase 2 basket trial enrolled adult patients in Europe and the United States who had a pathologically proven diagnosis of SCLC, ECOG performance status of ≤2, measurable disease per RECIST version 1.1, no brain metastasis, and adequate organ function.1 These patients received treatment with only 1 previous chemotherapy-containing regimen before study initiation.1

Treatment consisted of lurbinectedin (3.2 mg/m2) administered as a 1-hour intravenous infusion every 3 weeks until disease progression or unacceptable toxicity.1 The primary outcome of this study was the proportion of patients with an ORR, including complete or partial response, as assessed by investigators using RECIST criteria.1

Between October 2015 and January 2019, 105 patients with progressive SCLC were enrolled and treated with lurbinectedin. After median follow-up of 17.1 months, the ORR determined by investigator assessment was 35% (95% CI, 26%-45%).1 Median DOR was 5.3 months (95% CI, 4.1-6.4).2 Per independent review committee, the ORR was 30% (95% CI, 22%-40%) with median DOR of 5.1 months (95% CI, 4.9-6.4).2

The most common AEs (≥20%) were myelosuppression, fatigue, nausea, decreased appetite, musculoskeletal pain, constipation, dyspnea, vomiting, cough, and diarrhea.2 The most common grade 3 and 4 AEs included hematologic abnormalities, specifically neutropenia (46%), leukopenia (29%), anemia (9%), and thrombocytopenia (7%).1 Serious treatment-related AEs occurred in 10% of patients; neutropenia and febrile neutropenia were most frequent (5% each). No treatment-related deaths were reported.1

Researchers concluded that lurbinectedin is active as second-line therapy for SCLC in terms of ORR and had an acceptable and manageable safety profile.1 In June 2020, the US Food and Drug Administration granted lurbinectedin accelerated approval as a new treatment for patients with advanced SCLC who have progressed after platinum-based chemotherapy.2

References
1. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645-654.
2. US Food and Drug Administration. FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer. June 16, 2020. www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer. Accessed November 29, 2020.

Related Items
Sotorasib Achieves Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy May Be a New Standard of Care in Resectable NSCLC
Phoebe Starr
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Lung Cancer
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Last modified: July 22, 2021